Ticagrelor and Clopidogrel on Platelet Aggregation in Clopidogrel Resistance's Patients With CHD
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03614832|
Recruitment Status : Recruiting
First Posted : August 3, 2018
Last Update Posted : August 3, 2018
The study sought to observe the effects of optimal dose of ticagrelor（90 mg qd）ticagrelor and double standard-dose clopidogrel on platelet reactivity in coronary heart disease patients with high on-treatment platelet reactivity (HTPR) while on clopidogrel.
HTPR with clopidogrel administration in coronary heart disease (CHD) patients has associated with an increased risk of adverse events. Newer P2Y12 inhibitors ticagrelor (90mg BID) provide stronger platelet inhibition compared with clopidogrel, but a low-dose of ticagrelor (90mg QD) has not been previously studied in Chinese CHD patients with HTPR.
|Condition or disease||Intervention/treatment||Phase|
|Platelet Reactivity||Drug: Ticagrelor 90 mg Drug: Clopidogrel 150 mg||Phase 4|
Dual antiplatelet therapy (DAPT) with aspirin and P2Y12 receptor inhibitor has been the mainstay for the prevention of recurrent ischemic events in ACS patients and in those undergoing PCI. However, clopidogrel shows major individual variation in its antiplatelet effect in association with an increased incidence of ischemic events and stent thrombosis in patients with High on-treatment platelet reactivity (HTPR). There are several possible mechanisms of clopidogrel response variability or "resistance". Recently, it has been reported that a marked decrease in platelet response to clopidogrel is highly associated with the CYP2C19*2 loss-of-function allele, leading to an adverse prognosis.
Ticagrelor is the first reversibly binding, oral, direct acting P2Y12 receptor antagonist. Increasing studies showed that ticagrelor has a more rapid onset of effect and greater inhibition of platelet aggregation compared with clopidogrel. Recently, it has been reported that low-dose ticagrelor either with 90 mg QD or 45 mg BID, was associated with a more potent antiplatelet effect compared with clopidogrel treatment and once daily dose provided similar antiplatelet effect but favorable effect on optimal platelet inhibition compared with twice daily dose. Hiasa et al. identified that ticagrelor 45 mg twice daily was associated with enhanced inhibition of platelet aggregation (IPA) compared with clopidogrel 75 mg once daily in 118 Japanese patients with stable CAD. In our previous study, the investigators found that half-dose ticagrelor produced similar inhibitory effects on platelet aggregation as standard-dose ticagrelor and exerted significantly stronger effects than clopidogrel in patients with ACS and one-quarter standard-dose ticagrelor provided greater degree of platelet inhibition than clopidogrel in patients with stable CAD. Furthermore, standard-dose ticagrelor (180mg loading dose [LD], then 90mg twice daily) has a significant increase in the risk of bleeding and incidence rate of dyspnea, and that higher discontinuation rates due to adverse effects compared to clopidogrel. A recent study demonstrated that maximum plasma concentration and area under the plasma concentration-time curve of ticagrelor (90 mg twice daily) and its active metabolite (AR-C124910XX) tended to be approximately 40% higher in healthy Chinese volunteers compared with Caucasian subjects. Notably, poor drug metabolism of clopidogrel is more common in Asian populations compared with other international regions, due to the prevalence of CYP2C19 reduced-function alleles. The data suggested that a low dose of ticagrelor might be more appropriate for Chinese patients. Therefore, the optimal dose of ticagrelor for Chinese patients with HTPR is increasingly urgent.
So the objectives of this clinical study were to evaluate the effects of optimal dose of ticagrelor（90 mg qd）ticagrelor and double standard-dose clopidogrel on platelet reactivity in Chinese CHD patients with HTPR.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||100 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||Optimal Dose of Ticagrelor（90 mg qd）and Double Standard-dose Clopidogrel on Platelet Aggregation in Clopidogrel Resistance's Patients With Coronary Heart Disease|
|Actual Study Start Date :||May 1, 2018|
|Estimated Primary Completion Date :||May 1, 2019|
|Estimated Study Completion Date :||October 1, 2019|
Experimental: Ticagrelor 90 mg
To observe low-dose of ticagrelor（90 mg once daily oral）on platelet aggregation in clopidogrel resistance's patients with coronary heart disease.
Drug: Ticagrelor 90 mg
half-dose ticagrelor treatment (90 mg loading dose, then 90 mg once daily) for 1 week.
Active Comparator: Clopidogrel 150 mg
To observe double standard-dose clopidogrel （150 mg once daily oral）on platelet aggregation in clopidogrel resistance's patients with coronary heart disease.
Drug: Clopidogrel 150 mg
double standard-dose clopidogrel treatment (150 mg loading dose, then 150 mg once daily) for 1 week.
- The plateletinhibition ratio. [ Time Frame: up to 7 days ]Thromboelastography (TEG) was used to measure platelet inhibition ratio.
- The platelet aggregation ratio. [ Time Frame: up to 7 days ]Light transmission aggregometry method was used to measure platelet aggregation
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03614832
|Contact: Guangzhong Liu, PhDemail@example.com|
|Contact: Yue Li, PhDfirstname.lastname@example.org|
|the first affiliated hospital of Harbin medical university||Recruiting|
|Harbin, Heilongjiang, China, 150001|
|Contact: Yue Li, PhD|
|Principal Investigator:||Yue Li, PhD||First Affiliated Hospital of Harbin Medical University|